西罗莫司治疗新生儿卡波西样血管内皮瘤及卡萨巴赫-梅里特现象
Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate.
作者信息
Cabrera Trevor B, Speer Allison L, Greives Matthew R, Goff Donna A, Menon Neethu M, Reynolds Eric W
机构信息
Department of Pediatrics, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas.
Department of Pediatric Surgery, University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas.
出版信息
AJP Rep. 2020 Oct;10(4):e390-e394. doi: 10.1055/s-0040-1718901. Epub 2020 Nov 16.
We present a case of a neonate born with kaposiform hemangioendothelioma (KHE), complicated by Kasabach-Merritt phenomenon (KMP) and other serious conditions, who was successfully treated with sirolimus. In addition to complications from thrombocytopenia and fluid overload, during the course of therapy, our patient experienced supratherapeutic drug levels at the commonly accepted starting dose of sirolimus. Patients with KHE and KMP should be closely monitored for potential complications of both the initial disease and unexpected side effects of treatments.
我们报告了一例患有卡波西样血管内皮瘤（KHE）并伴有卡萨巴赫-梅里特现象（KMP）及其他严重病症的新生儿，该患儿通过西罗莫司成功治愈。除血小板减少和液体超负荷引起的并发症外，在治疗过程中，我们的患者在西罗莫司通常认可的起始剂量下出现了超治疗药物水平。患有KHE和KMP的患者应密切监测初始疾病的潜在并发症以及治疗的意外副作用。
Zotero 插件